|View printer-friendly version|
|Medtronic to Unveil Additional Clinical Data on HVAD® System at ISHLT 2018|
Data on Implant Approach, Blood Pressure Management, Length of Stay, and Quality of Life
DUBLIN - April 9, 2018 - Medtronic plc (NYSE: MDT) today announced a preview of notable clinical data on the HeartWare HVAD® System that will be presented at The International Society of Heart and Lung Transplantation (ISHLT) Scientific Sessions, from April 11-14, 2018, in Nice, France. The HVAD System is a mechanical heart pump (also called a left ventricular assist device, or LVAD) that helps increase the amount of blood that flows through the body in patients with advanced heart failure.
"ISHLT is the pre-eminent gathering of clinicians involved in caring for patients with advanced heart or lung disease, including heart transplants and mechanical circulatory support. Medtronic is pleased to collaborate with physicians to share the latest clinical evidence that advances MCS therapy," said Mike Hess, general manager of the Mechanical Circulatory Support business, part of the Cardiac and Vascular Group at Medtronic.
The congress agenda highlights several presentations featuring the HVAD System (all times CEST):
Wednesday, April 11
Thursday, April 12
Friday, April 13
Saturday, April 14
Featured posters include:
Details such as times, presenters and locations are subject to change.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.